Connection

MEGHANA TRIVEDI to Antineoplastic Agents

This is a "connection" page, showing publications MEGHANA TRIVEDI has written about Antineoplastic Agents.
Connection Strength

1.124
  1. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer. 2019 Mar 12; 19(1):220.
    View in: PubMed
    Score: 0.335
  2. Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer. Pharmacotherapy. 2013 Oct; 33(10):1126-9.
    View in: PubMed
    Score: 0.225
  3. Eribulin: a novel cytotoxic chemotherapy agent. Ann Pharmacother. 2012 Jun; 46(6):802-11.
    View in: PubMed
    Score: 0.209
  4. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncol. 2008 Aug; 4(4):483-500.
    View in: PubMed
    Score: 0.161
  5. GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat. 2018 Jul; 170(2):279-292.
    View in: PubMed
    Score: 0.078
  6. The incidence of tumor cell contamination of peripheral blood stem cells: a meta-analysis to evaluate the impact of mobilization regimens and the influence on outcomes in breast cancer patients. Acta Haematol. 2014; 131(3):133-40.
    View in: PubMed
    Score: 0.058
  7. Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1265-71.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.